文献速递物质与行为成瘾焦虑、强迫与应激相关障碍心境障碍

代谢型谷氨酸受体2/3作为治疗尼古丁成瘾的靶点

Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction.
PubMed 文献 · Biol Psychiatry · 2017-11-21

本文聚焦综述指出,突触前抑制性代谢型谷氨酸受体2/3(mGluR2/3)作为谷氨酸能末梢的关键自身受体,在尼古丁成瘾的获得、维持、戒断及长期戒断后复吸中起重要作用。mGluR2/3还参与焦虑、抑郁、精神分裂症等神经精神疾病,提示其可能为吸烟与这些疾病共病提供有效治疗途径,并作为与现有FDA批准药物机制不同的戒烟新靶点。

要点

  • mGluR2/3是维持谷氨酸稳态的突触前抑制性自身受体。
  • mGluR2/3参与尼古丁成瘾的获得、维持、戒断和长期戒断后复吸。
  • mGluR2/3靶向药物可能治疗吸烟与焦虑、抑郁等共病。

核心结论

  • mGluR2/3为开发机制不同于现有FDA批准疗法的戒烟药物提供了有前景的靶点。

研究设计与样本

  • 本文为聚焦综述,基于谷氨酸能神经传递在药物成瘾中作用的已有证据,汇总mGluR2/3与尼古丁成瘾及共病神经精神疾病的相关研究。

主要发现

  • mGluR2/3在尼古丁成瘾的不同方面起关键作用,包括尼古丁摄取的获得与维持、尼古丁戒断以及长期戒断后持续寻求尼古丁。
  • mGluR2/3还参与焦虑、抑郁、精神分裂症、阿尔茨海默病、帕金森病和疼痛等神经精神疾病。

关键数值与推荐

  • mGluR2/3参与尼古丁成瘾的获得与维持、戒断及长期戒断后持续寻求尼古丁。
  • mGluR2/3参与焦虑、抑郁、精神分裂症、阿尔茨海默病、帕金森病和疼痛。

临床怎么用

  • 提示可关注mGluR2/3作为戒烟药物新靶点,并考虑其用于吸烟与焦虑、抑郁等共病的潜在治疗价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tobacco smoking, driven by the addictive properties of nicotine, continues to be a worldwide health problem. Based on the well-established role of glutamatergic neurotransmission in drug addiction, novel medication development strategies seek to halt nicotine consumption and prevent relapse to tobacco smoking by modulating glutamate transmission. The presynaptic inhibitory metabotropic glutamate receptors 2 and 3 (mGluR2/3) are key autoreceptors on glutamatergic terminals that maintain glutamate homeostasis. Accumulating evidence suggests the critical role of mGluR2/3 in different aspects of nicotine addiction, including acquisition and maintenance of nicotine taking, nicotine withdrawal, and persistent nicotine seeking even after prolonged abstinence. The involvement of mGluR2/3 in other neuropsychiatric conditions, such as anxiety, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and pain, provides convincing evidence suggesting that mGluR2/3 may provide an effective therapeutic approach for comorbidity of smoking and these conditions. This focused review article highlights that mGluR2/3 provide a promising target in the search for smoking cessation medication with novel mechanisms of actions that differ from those of currently U.S. Food and Drug Administration-approved pharmacotherapies.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cross AJ, Anthenelli R, Li X, et al. Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction. Biol Psychiatry. 2017. PMID: 29301614. doi:10.1016/j.biopsych.2017.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。